540779-36-0

Usage

Uses

Used in Organic Synthesis:
[3-(BENZYLOXY)-4-BROMOPHENYL]METHANOL is used as a building block in the synthesis of complex organic compounds. Its unique structure allows for the creation of a wide range of molecules with diverse properties and potential applications.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, [3-(BENZYLOXY)-4-BROMOPHENYL]METHANOL is utilized as a key component in the development of biologically active molecules and pharmaceuticals. Its structural features make it a valuable asset in the design and synthesis of new drugs with potential therapeutic benefits.
Used in Pharmaceutical Industry:
[3-(BENZYLOXY)-4-BROMOPHENYL]METHANOL is used as a reagent in the pharmaceutical industry for the preparation of various biologically active molecules. Its presence in the synthesis process can lead to the development of new drugs with improved efficacy and reduced side effects.
Used in Research and Development:
This chemical compound is also employed in research and development settings, where it can be used to explore new reaction pathways, study the effects of structural modifications on molecular properties, and contribute to the advancement of scientific knowledge in the fields of organic chemistry and medicinal chemistry.

Upstream product

• 7781-98-8 ethyl-3-hydroxybenzoate 
• 99-06-9 3-Carboxyphenol 
• 540779-35-9 ethyl 4-bromo-3-benzyloxybenzoate 
• 100-39-0 benzyl bromide 
• 14348-38-0 4-bromo-3-hydroxybenzoic acid 
• 124318-23-6 3-Benzyloxy-4-brombenzoesaeure-benzylester 
• 33141-66-1 ethyl 4-bromo-3-hydroxybenzoate 

Relevant academic research and scientific papers

DIHYDROQUINOLIZINONES AS ANTIVIRALS

Compounds, specifically hepatitis B virus and/or hepatitis D virus inhibitors, more specifically compounds that inhibit HBe antigen and HBs antigen in a subject, for the treatment of viral infections, and methods of preparing and using such compounds. Formula (I):

Antagonist analogue of 6-[3′-(1-adamantyl)-4′-hydroxyphenyl]-2- naphthalenecarboxylic acid (AHPN) family of apoptosis inducers that effectively blocks AHPN-induced apoptosis but not cell-cycle arrest

The retinoid 6-[3′-(1-adamantyl)-4′-hydroxyphenyl]-2- naphthalenecarboxylic acid (AHPN) and its active analogues induce cell-cycle arrest and programmed cell death (apoptosis) in cancer cells independently of retinoic acid receptor (RAR) interaction. Its analogue, (E)-4-[3′-(1- adamantyl)-4′-hydroxyphenyl]-3-(3′-acetamidopropyloxy)cinnamic acid (3-A-AHPC) selectively antagonized cell apoptotic events (TR3/nur77/NGFI-B expression and nuclear-to-mitochondrial translocation) but not the proliferative events (cell-cycle arrest and p21WAF1/CIP1 expression) induced by proapoptotic AHPN and its analogues. The syntheses of 3-A-AHPC and proapoptotic (E)-6-[3′-(1-adamantyl)-4′-hydroxyphenyl]-5- chloronaphthalenecarboxylic acid (5-Cl-AHPN) are described. Computational studies on AHPN, AHPC, and three substituted analogues (5-Cl-AHPN, 3-Cl-AHPC, and 3-A-AHPC) suggested reasons for their diametric effects on RAR activation. Density functional theory studies indicated that the 1-adamantyl (1-Ad) groups of the AHPN and AHPC configurations assumed positions that were nearly planar with the aromatic rings of their polar termini. In contrast, in the configurations of the substituted analogues having chloro and 3-acetamidopropyloxy groups, rather than a hydrogen, ortho to the diaryl bonds, the diaryl bond torsion angles increased so that the 1-Ad groups were oriented out of this plane. Docking and molecular dynamics of AHPN, AHPC, and these substituted analogues in the RARγ ligand-binding domain illustrated how specific substituents on the AHPN and AHPC scaffolds modulated the positions and dynamics of the 1-Ad groups. As a result, the position of RARγ helix H12 in forming the coactivator-binding site was impacted in a manner consistent with the experimental effect of each analogue on RARγ transcriptional activation.

Induction of apoptosis in cancer cells

The present invention provides compounds that are inducers or inhibitors of apoptosis or apoptosis preceded by cell-cycle arrest. In addition, the present invention provides pharmaceutical compositions and methods for treating mammals with leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells.